MEDIFLY Maggots™ is cleared for the debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds. The prescription product consists of medical-grade fly larvae applied to a wound under the supervision of trained healthcare professionals to remove dead and infected tissue and support the body's natural healing process.

Chronic non-healing wounds, including diabetic foot ulcers and pressure injuries, affect millions of patients and place a significant and growing burden on health systems. It is estimated that 1-2% of the population in developed countries suffer from chronic wounds [Falanga et al., 2022]. With FDA clearance, MEDIFLY Maggots™ should soon become available to wound-care providers across the United States. As a biological, non-antibiotic approach to wound debridement, MDT is also drawing renewed interest amid global concern over antimicrobial resistance.